Chapter

Nanoformulated Medicines

Upal Roy, Shantanu Balkundi, JoEllyn McMillan and Howard E. Gendelman

in The Neurology of AIDS

Third edition

Published on behalf of Oxford University Press

Published in print December 2011 | ISBN: 9780195399349
Published online September 2012 | e-ISBN: 9780199965199 | DOI: http://dx.doi.org/10.1093/med/9780195399349.003.0070
Nanoformulated Medicines

More Like This

Show all results sharing these subjects:

  • Disorders of the Nervous System
  • Infectious Diseases

GO

Show Summary Details

Preview

Nanomaterials are being exploited with the goals to improve antiretroviral therapeutic efficacy, pharmacokinetics, and patient compliance. Importantly such materials can also be used for bioimaging to improve disease diagnosis and therapeutic monitoring. The targeted objectives all together are to attenuate human immunodeficiency virus (HIV) infection and positively affect the outcomes of disease manifestations in the infected human host. We posit that antiretroviral therapy delivery can be enhanced by formulating or encapsulating drugs with surfactants. Such nanoformulated drugs are readily taken up by the reticuloendothelial system (RES), the natural target for HIV. Recent works have explored the development of cell-based delivery systems using macrophages as drug carriers. This scheme has been shown to enhance nervous system RES delivery as macrophages are actively phagocytic cells and readily cross tissue barriers. Another major advantage of using cells as drug carriers is the potential to deliver a broad range of medicines with different biochemical properties to disease sites. This chapter discusses the potentials and perils for nanoformulated drug developments, with a particular focus on antiretroviral agents.

Chapter.  10568 words.  Illustrated.

Subjects: Disorders of the Nervous System ; Infectious Diseases

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.